Zobrazeno 1 - 10
of 596
pro vyhledávání: '"Giuseppe Paolisso"'
Autor:
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, Ada Pesapane, Manuela Giovanna Basilicata, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Maria Teresa Vietri, Annalisa Capuano, Giuseppe Paolisso, Michelangela Barbieri
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-13 (2024)
Abstract Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors. This drug has demonstrated great potential in improving the clinical outcomes of patients with type 2 diabetes. It can lead
Externí odkaz:
https://doaj.org/article/4ca156c215ba43d686dcdf0858b6834f
Autor:
Fatemeh Taktaz, Lucia Scisciola, Rosaria Anna Fontanella, Ada Pesapane, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Eduardo Sommella, Giuseppe Signoriello, Fabiola Olivieri, Michelangela Barbieri, Giuseppe Paolisso
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-15 (2024)
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective antidiabetic drugs with potential cardiovascular benefits. Despite their well-established role in reducing the risk of major adverse cardiovascular events (MACE),
Externí odkaz:
https://doaj.org/article/84a24c088642420db1de6f8e5cb9fb78
Autor:
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, Pier Francesco Rambaldi, Carlo Fumagalli, Ludovica Vittoria Marfella, Rosalba La Grotta, Chiara Frigé, Valeria Pellegrini, Davide D’Andrea, Arturo Cesaro, Paolo Calabrò, Carmine Pizzi, Roberto Antonicelli, Antonio Ceriello, Ciro Mauro, Giuseppe Paolisso
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Background Few studies explored the effect of the combination of glucose sodium-cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on the incidence of cardiovascular events in patients with type 2 di
Externí odkaz:
https://doaj.org/article/132b9c512d1a4999b08bdb1d8a813312
Autor:
Rosaria Anna Fontanella, Puja Ghosh, Ada Pesapane, Fatemeh Taktaz, Armando Puocci, Martina Franzese, Maria Federica Feliciano, Giovanni Tortorella, Lucia Scisciola, Eduardo Sommella, Concetta Ambrosino, Giuseppe Paolisso, Michelangela Barbieri
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background Several evidence demonstrated that glucagon-like peptide 1 receptor agonists (GLP1-RAs) reduce the risk of dementia in type 2 diabetes patients by improving memory, learning, and overcoming cognitive impairment. In this study, we
Externí odkaz:
https://doaj.org/article/3333edaddaa141dcabd6c2bdbfa2fe10
Autor:
Michele Cerasuolo, Irene Di Meo, Maria Chiara Auriemma, Giuseppe Paolisso, Michele Papa, Maria Rosaria Rizzo
Publikováno v:
Biomolecules, Vol 14, Iss 11, p 1362 (2024)
Aging induces complex changes in the lipid profiles across different areas of the brain. These changes can affect the function of brain cells and may contribute to neurodegenerative diseases such as Alzheimer’s disease. Research shows that while th
Externí odkaz:
https://doaj.org/article/094abd752aa546d7a04199499ae9450d
Autor:
Celestino Sardu, Ludovica Vittoria Marfella, Valerio Giordano, Caterina Claudia Lepre, Giovanbattista D’Amico, Mario Volpicelli, Carla Contaldi, Raffaele Galiero, Alfredo Caturano, Flavia Casolaro, Ferdinando Carlo Sasso, Carlo Uran, Domenico Cozzolino, Maddalena Nicoletti, Giuseppe Signoriello, Giuseppe Paolisso, Raffaele Marfella
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundLeft bundle branch (LBB) pacing could achieve cardiac resynchronization therapy (CRT) in patients who cannot be resynchronized via the placement of the left ventricle (LV) lead into the coronary sinus. LBB pacing could improve cardiovascula
Externí odkaz:
https://doaj.org/article/dfe306813e7742218d7fd3ffbc5beebd
Autor:
Michelangela Barbieri, Paolo Chiodini, Piergiacomo Di Gennaro, Gaye Hafez, Sophie Liabeuf, Jolanta Malyszko, Laila-Yasmin Mani, Francesco Mattace-Raso, Marion Pepin, Norberto Perico, Mariadelina Simeoni, Carmine Zoccali, Giovanni Tortorella, Annalisa Capuano, Giuseppe Remuzzi, Giovambattista Capasso, Giuseppe Paolisso
Publikováno v:
Pharmacological Research, Vol 203, Iss , Pp 107146- (2024)
Patients with chronic kidney disease (CKD) often experience mild cognitive impairment and other neurocognitive disorders. Studies have shown that erythropoietin (EPO) and its receptor have neuroprotective effects in cell and animal models of nervous
Externí odkaz:
https://doaj.org/article/b20da874e82f40b4897517a2fb0f6b4c
Autor:
Lucia Scisciola, Ugo Chianese, Vicky Caponigro, Manuela Giovanna Basilicata, Emanuela Salviati, Lucia Altucci, Pietro Campiglia, Giuseppe Paolisso, Michelangela Barbieri, Rosaria Benedetti, Eduardo Sommella
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-15 (2023)
Abstract Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) has shown beneficial effects against heart failure. Because cardiovas
Externí odkaz:
https://doaj.org/article/f9085a4fe01747819d1ef129d4319709
Autor:
Celestino Sardu, Maria Consiglia Trotta, Ferdinando Carlo Sasso, Cosimo Sacra, Gerardo Carpinella, Ciro Mauro, Fabio Minicucci, Paolo Calabrò, Michele D’ Amico, Fabrizio D’ Ascenzo, Ovidio De Filippo, Mario Iannaccone, Carmine Pizzi, Giuseppe Paolisso, Raffaele Marfella
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-15 (2023)
Abstract Background Sodium–glucose transporter 2 inhibitors (SGLT2-I) could modulate atherosclerotic plaque progression, via down-regulation of inflammatory burden, and lead to reduction of major adverse cardiovascular events (MACEs) in type 2 diab
Externí odkaz:
https://doaj.org/article/c47e5c4bbd454170b666cf4398702fcc
Autor:
Annamaria Mascolo, Concetta Rafaniello, Gabriella di Mauro, Donatella Ruggiero, Maria Rosaria Campitiello, Maria Donniacuo, Pasquale Maria Berrino, Francesco Rossi, Giuseppe Paolisso, Annalisa Capuano
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: The risk of falls and bone fractures with sodium-glucose co-transporter-2 (SGLT2) inhibitors has been characterized by conflicting evidence. Therefore, we decided to investigate the reporting probability of falls and fractures by comparin
Externí odkaz:
https://doaj.org/article/97a8df14b6444e94b8ba4424abab0e5f